Make-A-Wish: MaKya's story
RUSSELLVILLE, Ala. (WHNT) – Ahead of News 19's telethon benefiting Make-A-Wish Alabama, we want to introduce you to just a few of the 78 children in North Alabama who are Wish Kids.
They can't wait to see their wishes get granted, but it takes donations to make it happen. One of those children waiting for her wish is MaKya.
The eight-year-old is always on the move.
'She's playing softball, she does baton, and she does the cheerleading clinics in school,' Mom ReShanga Baker said.
When she's not doing extracurriculars, her family said she is always getting into something at home. She loves playing outside too.
Not only is she a young athlete, but she excels in school. Her favorite subject is Math.
After class, after-school activities, and homework, it's time for bed. Before she sleeps, however, she must be hooked up to her TPN machine for a nine-hour run. It's connected through a central line in her chest.
'It's like a catheter. It gives her nutrients she doesn't get by mouth with her small intestine,' ReShanga said. 'Her digestive system is different from ours.'
MaKya was born with only 10% of her small intestine. ReShanga said before she was born, doctors believed she had a cyst. When she entered the world, ReShanga said she was immediately flown to Huntsville Hospital for emergency treatment. She didn't get to meet her daughter until two days later.
'[Doctors] say she had, basically, something like gangrene. They went in and cut out the part. She was lying in the incubator with the tubes and stuff on her,' ReShanga said.
She didn't leave the hospital for five months. Now, MaKya has braved more surgeries than she's had years of life.
'She's probably had about 10 or 12 in total,' ReShanga said.
MaKya goes to her local doctor every month for checkups, then travels for an in-depth look at Children's a couple of times a year. MaKya said she doesn't mind the check-ups.
'Only when I have to go into surgeries, I'm scared,' MaKya said.
ReShanga said as long as her daughter's central line stays in tip-top shape, there may not need to be any more surgeries.
There was a silver lining when she had her last operation, though: MaKya discovered a love of Disney movies, especially 'Moana.'
After the operation, when she was five, ReShanga was connected with Make-A-Wish Alabama. MaKya said she wanted to go to Disney World.
'She was so excited. She was just yelling and jumping,' ReShanga said. 'To see her have a good time and enjoy herself. I think that's what I'm looking forward to.'
MaKya is bringing her older sister, her mom, and her stepdad with her on her trip. She can't wait to run through the parks and ride as many rides as she can.
If you're interested in helping Make-A-Wish Alabama grant wishes like MaKya's, you can donate to News 19's 'Wishes Can't Wait' telethon right now! Click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
Denver, June 06, 2025 (GLOBE NEWSWIRE) — BrainDefender Research today announced the launch of BrainDefender Memory Support Supplement , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. Availability BrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender Research BrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: [email protected] Phone: (855) 473-4405 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
a day ago
- Yahoo
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
Plant-Based Supplement Includes Five Individual Ingredients Studied for Their Role in Supporting Memory and Focus Denver, June 06, 2025 (GLOBE NEWSWIRE) -- BrainDefender Research today announced the launch of , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. AvailabilityBrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender ResearchBrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. DisclaimerThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: support@ Phone: (855) 473-4405 CONTACT: Email: support@ Phone: (855) 473-4405Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review. OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025. The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications. In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
